Rapid Prostate Cancer Screening Could Benefit African American Men - AARP

-
African American man sitting in a chair in a barbershop

Jetta Productions Inc / Getty Images

En español

A rapid prostate cancer screening kit could provide early warning to African American men and others at greater risk to the disease who may have limited access to health care, according to researchers at Cornell University.

In a proof-of-concept test, the scientists were able to show that a drop of blood on a test strip could be analyzed by a small portable reader for a prostate-specific antigen (PSA) that may indicate prostate cancer. The results of the test appear online in the journal Current Research in Biotechnology.

"We'll be able to take a drop of blood in a community setting such as a barbershop and be able to deliver results in 10 to 15 minutes right there, which can indicate when somebody needs to come in for further tests," study coauthor Saurabh Mehta, M.D., a professor of nutritional sciences at Cornell, said in a statement.

Similar test strips are used in at-home COVID-19 antigen tests and pregnancy tests, but Mehta and his fellow researchers used one designed to be more sensitive to PSAs. They also utilized a reader that calculates and displays a measurement of PSA concentration in the blood rather than simply giving a positive or negative result, like a pregnancy test does.

a a r p membership card

AARP Membership — $12 for your first year  when you sign up for Automatic Renewal

Join today and get instant access to discounts, programs, services, and the information you need to benefit every area of your life. 

A study published in the Journal of the National Cancer Institute in 2020 pointed out that prostate cancer is the second-leading cause of cancer death in men in the United States, with approximately 192,000 new cases and 33,000 deaths that year. It also noted that rates of late-stage prostate cancer were two to three times higher in Black men than in white men ages 20–74. Genetics, as well as lifestyle factors such as smoking and obesity, are thought to play a role in that disparity, though more research is needed.

The scientists recently received funding from the U.S. Department of Defense that will allow them to continue their research and test the device in certain underserved neighborhoods in New York in partnership with other colleagues at Cornell.

More on Prostate Cancer​ 

  • More information is better for prostate cancer screening​
  • Rates of advanced prostate cancer have climbed​
  • ​Should you get genetic testing for prostate cancer?​

Comments

Post a Comment

Popular posts from this blog

Sentinel lymph node biopsy: What cancer patients should know

-
Image
cancer lump on neck :: Article Creator Doctor Watching TV Show Spotted Cancer On Show's Guest That She Didn't Know About Say what you will about social media and daytime TV, but sometimes, they can help work wonders. In fact, the power of Facebook and the popularity of HGTV's Beachfront Bargain Hunt played a big part in helping Nicole McGuiness get ahead of her serious cancer diagnosis - but it was an eagle-eyed doctor who really saved her bacon. The then-32-year-old appeared on the property series alongside her father while in search of a holiday home in North Carolina to celebrate her recent recovery from brain cancer in May 2018. She explained that she had set her sights on 'something near the water', specifically a beachfront property in Morehead City, to start afresh in this new phase of her life. Dr. Erich Voigt was one of the viewers who tuned into the Beachfront Bargain Hunt episode, which Nicole featured in, an...
Read more

Expert Discusses Data From First Positive Trial for PARP Inhibitor in Prostate Cancer - Targeted Oncology

-
Image
Alan Bryce, MD PARP inhibition with olaparib (Lynparza) improved radiographic progression-free survival (rPFS) in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) who had alterations in homologous recombination repair (HRR) genes, according to findings from the phase III PROfound trial presented at the 2019 ESMO Congress. This was the first positive randomized phase III trial reported evaluating a PARP inhibitor in men with mCRPC. The PROfound trial enrolled patients to 2 cohorts. In cohort A, 245 patients with  BRCA1/2  or  ATM  alterations, markers of HRR, were randomized 2:1 to receive either olaparib (n = 162) or physician’s choice of abiraterone acetate (Zytiga) with prednisone or enzalutamide (Xtandi) (n = 83). In cohort B, 142 patients with alterations in the  BARD1, BRIP1, CDK12, CHEK1/2, FANCL, PALB2, PPP2R2A, RAD51B/C/D , or  RAD54L , all of which are associated with HRR indirectly, were also randomized 2:...
Read more

Prostate MRI in Stereotactic Body Radiation Treatment Planning and Delivery for Localized Prostate Cancer - RSNA Publications Online

-
Image
Abstract In patients with prostate cancer, prostate MRI can be used to detect and diagnose disease, identify dominant intraprostatic lesions that may be treated with a higher radiation dose, help segment radiation treatment targets, and evaluate fiducial marker and hydrogel spacer placements for radiation treatment planning and delivery. Prostate MRI is increasingly being used to make diagnoses and guide management for patients receiving definitive radiation treatment for prostate cancer. Radiologists should be familiar with the potential uses of prostate MRI in radiation therapy planning and delivery. Radiation therapy is an established option for the definitive treatment of localized prostate cancer. Stereotactic body radiation therapy (SBRT) is an external-beam radiation therapy method used to deliver a high dose of radiation to an extracranial target in the body, often in five or fewer fractions. SBRT is increasingly being used for prostate cancer treatment and has been recognized ...
Read more